Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Equity Average (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Equity Average for 6 consecutive years, with $587.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 27.33% to $587.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $587.4 million, a 27.33% decrease, with the full-year FY2025 number at $672.4 million, down 12.09% from a year prior.
  • Equity Average was $587.4 million for Q4 2025 at Relay Therapeutics, down from $636.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $975.0 million in Q4 2022 to a low of $587.4 million in Q4 2025.
  • A 5-year average of $766.0 million and a median of $754.9 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 415.92% in 2021, then dropped 27.33% in 2025.
  • Relay Therapeutics' Equity Average stood at $734.4 million in 2021, then surged by 32.75% to $975.0 million in 2022, then dropped by 21.52% to $765.2 million in 2023, then rose by 5.64% to $808.3 million in 2024, then decreased by 27.33% to $587.4 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Equity Average are $587.4 million (Q4 2025), $636.7 million (Q3 2025), and $693.4 million (Q2 2025).